Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada clears Intercept blood pathogen inactivator:

This article was originally published in Clinica

Executive Summary

Baxter and Cerus have gained Canadian market approval for what they claim is the first pathogen inactivation system approved in the country for use with platelets intended for transfusion. The Intercept blood system, which was recently approved in Europe (see Clinica No 1029, p 25), is cleared in Canada for use with platelets prepared using the buffy coat method, says Cerus. The firm notes that though Canada currently uses the platelet rich plasma and single donor platelet collection methods, the Canadian Blood Services and Hema Quebec are evaluating the possibility of implementing the buffy coat method. The firms plan to apply in early 2003 for permission to use their system with single-donor platelets.

Topics

UsernamePublicRestriction

Register

MT068687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel